CMS Sunshine Data And Ultra-Orphan Relationships: Aegerion May Have More Payments Than Patients
This article was originally published in RPM Report
Executive Summary
Data from CMS’ Open Payments shows Aegerion may have been making more payments to physicians than it had patients in its ultra-orphan segment of the hypercholesterolemia population.
You may also be interested in...
FDA-CMS Parallel Review Pilot Will Be Extended; Drugs Not The Focus
CMS remains open to the idea of using parallel review (or, less formal parallel advice) for prescription drugs, but the current and future focus of the pilot program is likely to stay on devices and diagnostics.
Personalized Medicine Meets Payment Policy: MEDCAC Has “Low Confidence” In Most Cancer Tests
Genomic screening of tumor types may be the cutting edge in cancer treatment and a central component of the President’s vision for personalized medicine. But how much evidence is necessary to make insurance coverage for testing routine?
Looking Forward At FDA: Hamburg’s Farewell Notes Challenges; Califf’s First Remarks Focus on Pediatrics
FDA Commissioner Margaret Hamburg is leaving the agency on a high note – and taking the opportunity to urge stakeholders to avoid the temptation to push for changes that will “”weaken or undermine” the agency. Meanwhile, FDA's new Deputy Commissioner of Medical Products Robert Califf makes his first formal remarks in that role during a stakeholder meeting on pediatric research.